FindTrial
Sign In

A Post-Approval Study of the PROMUS PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in China

A Post-Approval Study of the PROMUS PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016355
Enrollment
Unknown
Registered
2018-05-28
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

Case series:non intervention

Sponsors

Second Afiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subject must be at least 18 years of age; 2. Subject understands and provides written informed consent; 3. Subject who is clinically indicated and will have an attempt of at least one Promus PREMIERTM Stent; OR Subject who is clinically indicated and was implanted with at least one Promus PREMIERTM Stent; 4. Subject is willing to comply with all protocol-required follow-up evaluation.

Exclusion criteria

Exclusion criteria: Exclusion criteria are not required in the PE PREMIERTM China Post-Approval Study which is an all comers study.

Design outcomes

Primary

MeasureTime frame
MACE;—

Countries

China

Contacts

Public ContactChunlei Han
chunlei.han@fountain-med.com+86 13810393199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026